Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Studies from University of Vienna have provided new data on breast cancer
March 20th, 2008
"Neoadjuvant chemotherapy is the treatment of choice for locally-advanced breast cancer and leads to down staging and improved breast-conserving therapy (BCT) rates. While its efficacy is well established, considerably less is known about the most effective regimen," investigators in Vienna, Austria report. "We have performed a retrospective analysis of 132 breast cancer patients who had undergone neoadjuvant chemotherapy at our institution. Patients had either received a) anthracyclines (''A'', n=35), b) anthracyclines and taxanes (''AT'', n=55), or c) neither of the two compounds (''NoA/T'', n=42). Clinical response, pathological response and survival were evaluated...
Source: Women's Health Weekly (2008-03-20)
|
